Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pleiotropy01:33

Pleiotropy

Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Engineering immune niches: biochemical, mechanical, and spatial design principles for translational hydrogels.

Med-X·2026
Same author

Substrate-derived peptides for selective covalent inhibition of protein tyrosine kinases.

bioRxiv : the preprint server for biology·2026
Same author

Multiplexed single-cell transcriptomics reveals diverse phenotypic outcomes for pathogenic SHP2 variants.

Science advances·2026
Same author

Defining the heterogeneous molecular landscape of lung cancer cell responses to epigenetic inhibition.

Communications biology·2026
Same author

An expanded role for single-cell chemical genomics profiling in drug discovery.

The Biochemical journal·2026
Same author

Pervanadate: So much more than a protein tyrosine phosphatase inhibitor.

Science signaling·2026

Related Experiment Video

Updated: May 12, 2026

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia
05:51

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia

Published on: June 15, 2011

26.0K

Multiplexed single-cell transcriptomics reveals diverse phenotypic outcomes for pathogenic SHP2 variants.

Anne E van Vlimmeren1,2, Ross M Giglio3,4, Ziyuan Jiang1

  • 1Department of Chemistry, Columbia University, New York, NY 10027.

Biorxiv : the Preprint Server for Biology
|July 9, 2025
PubMed
Summary

Mutations in the SHP2 phosphatase gene (PTPN11) cause developmental disorders and cancer. Diverse mutations can lead to similar cell states, revealing complex links between SHP2 structure, signaling, and disease.

Keywords:
Noonan SyndromePTPN11cancermissense mutationmultiplex single-cell transcriptional profilingtyrosine phosphatase

More Related Videos

In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

20.8K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.3K

Related Experiment Videos

Last Updated: May 12, 2026

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia
05:51

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia

Published on: June 15, 2011

26.0K
In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

20.8K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.3K

Area of Science:

  • Molecular Biology
  • Genetics
  • Cell Biology

Background:

  • SHP2 phosphatase, encoded by PTPN11, regulates Ras/MAPK signaling downstream of transmembrane receptors.
  • PTPN11 mutations are linked to Noonan Syndrome and various cancers, with varied effects on SHP2 activity and interactions.
  • Understanding how distinct mutations dysregulate SHP2 is crucial for disease comprehension.

Purpose of the Study:

  • To elucidate the molecular mechanisms by which diverse PTPN11 mutations perturb SHP2 function and signaling.
  • To correlate structural changes in SHP2 variants with cellular and gene expression phenotypes.
  • To establish a framework linking SHP2 structural alterations to disease outcomes.

Main Methods:

  • Single-cell transcriptional profiling of cells expressing various SHP2 variants.
  • Protein biochemistry and structural analysis of SHP2 variants.
  • Cell biology assays to assess signaling and cellular phenotypes.

Main Results:

  • Loss of SHP2 catalytic activity does not fully replicate SHP2 knock-out gene expression profiles.
  • Mechanistically different SHP2 mutations can converge to produce similar cellular phenotypes.
  • Distinct mutations at the same residue can result in divergent cellular states.

Conclusions:

  • SHP2-driven diseases are complex, with mutations having varied effects beyond simple catalytic activity.
  • Convergent and divergent cellular outcomes arise from distinct SHP2 mutations.
  • This study provides a framework for understanding SHP2 mutation impact on cellular function and human disease.